Want to see TEVA full AI Analyst Report?
TEVA Stock Chart & Stats
$38.10
-$0.37(-1.19%)
At close: 4:00 PM EDT
$38.10
-$0.37(-1.19%)
Day’s Range― - ―
52-Week Range$16.74 - $40.79
Previous CloseN/A
Volume3.13M
Average Volume (3M)2.00M
Market Cap
$45.38B
Enterprise Value$154.00K
Total Cash (Recent Filing)$3.63B
Total Debt (Recent Filing)$16.76B
Price to Earnings (P/E)66.0
Beta-0.55
Next Earnings
Nov 03, 2026EPS Estimate
0.71Next Dividend Ex-DateN/A
Dividend Yield5.8%
Share Statistics
EPS (TTM)0.63
Shares Outstanding1,165,296,100
10 Day Avg. Volume5,548,479
30 Day Avg. Volume1,995,559
Financial Highlights & Ratios
PEG Ratio-0.14
Price to Book (P/B)4.58
Price to Sales (P/S)1.94
P/FCF Ratio14.18
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$44.75Price Target Upside17.45% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)0.02
Revenue Forecast (FY)$164.26M
Bulls Say, Bears Say
Bulls Say
Strong Cash GenerationTeva is converting operations into substantial cash, with free cash flow growing strongly and exceeding reported earnings support. This provides funding for debt reduction, product investment, and business development while improving resilience through the next several quarters.
Innovative Portfolio GrowthRapid growth in innovative medicines is gradually shifting Teva toward a more differentiated product mix. A larger innovation contribution can support better margins, reduce reliance on commoditized generics, and create a more durable growth platform.
Expanding Biosimilars PlatformThe Degevma approval expands Teva’s biosimilars presence in the U.S. and complements its existing denosumab product. Regulatory progress and a broader portfolio can strengthen commercial scale, diversify growth, and support the company’s target of exceeding $800M in biosimilars revenue by 2027.
Bears Say
Elevated LeverageTeva’s debt burden remains high relative to equity and operating earnings, limiting financial flexibility even though leverage has improved. The company must continue generating cash and executing its plan to reach below 2x net debt/EBITDA, leaving less cushion if earnings weaken.
Unstable Revenue GrowthThe sharp TTM revenue contraction raises concerns about the durability of Teva’s recovery, despite improved margins and profitability. Uneven top-line performance can limit operating leverage, complicate investment planning, and make sustained earnings expansion dependent on successful portfolio execution.
Persistent Generics PressureGenerics remain exposed to product losses, pricing pressure, and intense competition, with the REVLIMID comparison creating a material revenue gap. Management expects generics to be flat to down low single-digit in 2026, keeping pressure on the core business while innovation scales.
Teva News
TEVA FAQ
What was Teva Pharmaceutical Industries Limited’s price range in the past 12 months?
Teva Pharmaceutical Industries Limited lowest stock price was $16.74 and its highest was $40.79 in the past 12 months.
What is Teva Pharmaceutical Industries Limited’s market cap?
Teva Pharmaceutical Industries Limited’s market cap is $45.38B.
When is Teva Pharmaceutical Industries Limited’s upcoming earnings report date?
Teva Pharmaceutical Industries Limited’s upcoming earnings report date is Nov 03, 2026 which is in 33 days.
How were Teva Pharmaceutical Industries Limited’s earnings last quarter?
Teva Pharmaceutical Industries Limited released its earnings results on Jul 29, 2026. The company reported $0.02 earnings per share for the quarter, missing the consensus estimate of $0.051 by -$0.031.
Is Teva Pharmaceutical Industries Limited overvalued?
According to Wall Street analysts Teva Pharmaceutical Industries Limited’s price is currently Undervalued.
Does Teva Pharmaceutical Industries Limited pay dividends?
Teva Pharmaceutical Industries Limited pays a Quarterly dividend of $0.085 which represents an annual dividend yield of 5.8%. See more information on Teva Pharmaceutical Industries Limited dividends here
What is Teva Pharmaceutical Industries Limited’s EPS estimate?
Teva Pharmaceutical Industries Limited’s EPS estimate is 0.71.
How many shares outstanding does Teva Pharmaceutical Industries Limited have?
Teva Pharmaceutical Industries Limited has 1,165,296,100 shares outstanding.
What happened to Teva Pharmaceutical Industries Limited’s price movement after its last earnings report?
Teva Pharmaceutical Industries Limited reported an EPS of $0.02 in its last earnings report, missing expectations of $0.051. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Teva Pharmaceutical Industries Limited?
Currently, no hedge funds are holding shares in TEVA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Teva Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$44.75 (17.45% Upside)
$44.75 (17.45% Upside)
Blogger Sentiment
Bearish
TEVA Sentiment 100%
Sector Average ―
Sector Average ―
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
96.55%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-0.68%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Teva Pharmaceutical Industries Limited
Teva Pharmaceutical Industries Limited operates as a prominent global pharmaceutical firm, involved in the research, development, manufacturing, marketing, and distribution of generic, specialized, and biopharmaceutical products throughout North America, Europe, and other international regions. The company's diverse portfolio encompasses sterile preparations, hormonal therapies, high-potency drugs, and cytotoxic substances, supplied in a wide array of dosage forms such as tablets, capsules, injectable solutions, inhalants, oral liquids, transdermal patches, topical ointments, and creams. Furthermore, Teva develops, produces, and sells active pharmaceutical ingredients (APIs). A significant portion of its research and product development is concentrated on the central nervous system, pain management, respiratory illnesses, and oncology. Leading products for the central nervous system include Copaxone, utilized for relapsing multiple sclerosis; AJOVY, an option for migraine prevention; and AUSTEDO, prescribed for tardive dyskinesia and chorea linked to Huntington's disease. Within the respiratory domain, addressing asthma and chronic obstructive pulmonary disease, Teva offers products like ProAir, QVAR, various Digihaler and RespiClick formulations, along with BRALTUS and CINQAIR/CINQAERO. Their oncology division features treatments such as Bendeka, Treanda, Granix, Trisenox, Lonquex, and Tevagrastim/Ratiograstim. The company also collaborates with MedinCell on the creation and commercialization of multiple extended-release injectable products, including a risperidone suspension designed for individuals with schizophrenia. Teva Pharmaceutical Industries Limited was founded in 1901 and is headquartered in Tel Aviv-Yafo, Israel.
TEVA Revenue Breakdown
54.45% North America
32.42% Europe
13.12% International Markets
TEVA Stock 12 Month Forecast
Average Price Target
$44.75
▲(17.45% Upside)
Technical Analysis
Alkermes
―
Dr Reddy's Laboratories
―
Viatris
―
Perrigo Company
―
Amneal Pharmaceuticals
―
Ownership Overview
―
Insiders
2.80% Mutual Funds
<0.01% Other Institutional Investors
86.33% Public Companies and
Individual Investors